NanoViricides, Inc. (NNVC)
NYSEAMERICAN: NNVC · Real-Time Price · USD
1.210
-0.040 (-3.20%)
Apr 28, 2026, 4:00 PM EDT - Market closed
NanoViricides Employees
NanoViricides had 7 employees as of June 30, 2025. The number of employees did not change compared to the previous year.
Employees
7
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$1,188,349
Market Cap
26.13M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Longeveron | 38 |
| ABVC BioPharma | 19 |
| NeuroSense Therapeutics | 17 |
| Lantern Pharma | 16 |
| BriaCell Therapeutics | 16 |
| Barinthus Biotherapeutics | 14 |
| Apollomics | 13 |
| Neuphoria Therapeutics | 8 |
NNVC News
- 7 days ago - Deadly Measles Cases Accentuate the Need for a Treatment - NV-387 is Here to Help Patients and Control Spread, Says NanoViricides - Accesswire
- 21 days ago - Measles Rare Pediatric Disease Drug Designation Application Filed for NV-387, PRV Provides for Strong Business Case, Says NanoViricides - Accesswire
- 27 days ago - Phase II Clinical Trial of Monkeypox Treatment by NV-387 to Commence Soon, Announces NanoViricides - Accesswire
- 6 weeks ago - NanoViricides Presenting at NIBA's 152nd Investment Conference in Fort Lauderdale, FL March 12, 2026 - Announces Manufacture of Phase II Clinical Product NV-387 Oral Gummies is Complete - Accesswire
- 2 months ago - MPox Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides - Accesswire
- 2 months ago - Measles Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides - Accesswire
- 3 months ago - NanoViricides President Dr. Diwan Interviewed by Mission Matters' Adam Torres - Accesswire
- 3 months ago - NanoViricides Comments on the Need for Broad-Spectrum Antivirals in Light of the Current Influenza Wave - NV-387 is Effective Against H3N2 - Accesswire